The study of Dexmedetomidine with Ropivacaine in Eye Block for retina surgeries

Prospective randomized comparative study of adjuvant dexmedetomidine to 0.75 percent Ropivacaine with 0.75 percent ropivacaine alone in subtenon blocks for vitreoretinal surgeries - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072433

Enrollment

Registered

2024-08-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H330- Retinal detachment with retinal break

Interventions

Intervention1: 0.75% Ropivacaine with Dexmedetomidine 20mcg: Dexmedetomidine 20mcg with 0.75% Ropivacaine 5ml will be given in sub-tenons block prior to retinal surgery. Patient is monitored during s

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1,2,3 Satisfactory akinesia following subtenon blocks and predictable surgical time of less than 3hours

Exclusion criteria

Exclusion criteria: Known allergy to dexmedetomidines Patients with a single eye History of sleep apnea Severe Cardiac, respiratory and renal disease Drowsy on the day of surgery with Ramsay Level of Sedation Scale Score more than 3 Normal sinus bradycardia in ECG, Baseline Hypotension recorded Dementia Communication disabilities

Design outcomes

Primary

Measure	Time frame
Effect of the adjuvant added in sub-tenons block on motor and sensory block.Timepoint: 3months	—

Secondary

Measure	Time frame
Adverse effect associated with 20mcg Dexmedetomidine as adjuvant in subtenon blockTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Deepa Rakesh Sharma

Nethradhama Super Speciality Eye Hospital

yathirajdeepa@gmail.com08026088000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026